Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Key updates from the St Gallen Consensus Session

Hans-Christian Kolberg • 22 Mar 2021
BCC 2021
Breast Cancer
ADAPT

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany outlines key highlights from the virtual 17th St. Gallen International Breast Cancer Consensus session on the optimal treatment of women with early breast cancer, including how the results of the ADAPT trial (NCT01779206) will influence risk assessment of HR+ breast cancer patients. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

More from Hans-Christian Kolberg

Management of immune-related AEs during ICI therapy in the clinic
1:36
Management of immune-related AEs during ICI therapy in the clinic
Hans-Christian Kolberg • 12 Dec 2024
Predictive biomarkers for response to checkpoint inhibitors in TNBC
2:00
Predictive biomarkers for response to checkpoint inhibitors in TNBC
Hans-Christian Kolberg • 12 Dec 2024
Subgroup analysis from NeoMono: PD-L1 status and pCR in high-risk eTNBC
3:58
Subgroup analysis from NeoMono: PD-L1 status and pCR in high-risk eTNBC
Hans-Christian Kolberg • 12 Dec 2024
NeoMono: mono atezolizumab window followed by atezolizumab - CTX vs atezolizumab - CTX
3:57
NeoMono: mono atezolizumab window followed by atezolizumab - CTX vs atezolizumab - CTX
Hans-Christian Kolberg • 7 Dec 2022

Related Videos

How can genomic assays guide treatment in HR+/HER2- breast cancer?
1:26
How can genomic assays guide treatment in HR+/HER2- breast cancer?
Kevin Kalinsky • 25 Oct 2026
Disease control and patient-reported quality of life in the ASCENT-04 trial
0:56
Disease control and patient-reported quality of life in the ASCENT-04 trial
Kevin Kalinsky • 25 Oct 2026
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
1:02
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
Kevin Kalinsky • 25 Oct 2026
Treating triple negative early breast cancer after optimal neoadjuvant therapy
2:24
Treating triple negative early breast cancer after optimal neoadjuvant therapy
Joana Ribeiro • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals